« Previous | Next » | All Messages |  BIPH Message Board Home | recommend post |  Ignore Poster

BIPH News Biophan Announces William L. Holman, MD, Has Joined The MYOTECH Scientific Advisory Board

ROCHESTER, N.Y.--(BUSINESS WIRE)--Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, today announced that William L. Holman, MD, has joined the MYOTECH Scientific Advisory Board. MYOTECH and Biophan are co-developing the MYO-VAD™, a unique cardiac recovery system designed to treat many types of heart failure.

Jeffrey L. Helfer, President of Biophan’s Cardiovascular Division stated, “Dr. Holman’s extensive knowledge and experience in cardiothoracic surgery will be invaluable to the further development and clinical evaluation of the MYO-VAD.”

The MYO-VAD is a cardiac recovery system that can be installed around an arrested or weak heart in under three minutes, restoring cardiac output in both acute failure situations and for long-term support. Incorporating a pneumatically activated liner, the MYO-VAD operates by compressing and expanding bi-directionally, providing the energy that allows the heart to restore the output of blood to normal, life sustaining levels. Since it is not blood-contacting, unlike virtually all existing cardiac assist devices, the MYO-VAD has the potential to avoid complications, including clotting and stroke, bleeding, and infection. The MYO-VAD represents a major advance over traditional methods of cardiac support.

Dr. Holman has nearly twenty years experience in Cardiothoracic Surgery. He has been Chief of Cardiothoracic Surgery at the Birmingham VA Medical Center since 1988. Dr. Holman said, “The MYO-VAD technology for circulatory assistance has important advantages over other devices, and has the potential to improve survival in a challenging patient population. It is a pleasure to be a member of the MYOTECH Scientific Advisory Board.”

Biophan Technologies, Inc. holds a 42% interest in MYOTECH with rights to acquire a majority position, and is leading MYOTECH’s business development.

Dr. Holman is also currently a Professor in the Division of Cardiothoracic Surgery at the University of Alabama at Birmingham (since 1998), where he is also Senior Scientist at the Center for Outcomes and Effectiveness Research and Education (since 2001), and Senior Scientist at the University’s Center for Aging (since 2003).

He has served as a member and/or advisor to numerous boards and institutions. Dr. Holman received his undergraduate training at Williams College in Williamstown, MA and his medical studies were completed at Cornell University Medical College in New York City.

Information on the MYO-VAD can be found at www.biophan.com.

About Biophan

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company licenses its technologies which improve the MRI safety and image compatibility of medical devices to leading device manufacturers. In addition, the Company is commercializing the MYOTECH MYO-VAD™, a new, cardiac recovery system which has significant potential to improve the treatment of many forms of heart disease. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.